BTIM Stock: BioTime CEO Dr. Michael West Presents Keynote Address at Event Commemorating the 10th Anniversary of the First Derivation of Human Embryonic Stem Cells
BioTime, Inc. (OTCBB:BTIM stock) Chief Executive Officer Michael West, Ph.D.
will deliver a keynote presentation on Wednesday, November 19, at a
meeting in Madison, Wisconsin commemorating the 10th
anniversary of the publication describing the derivation and culturing
of human embryonic stem cells for the first time. Dr. West’s
presentation is titled “Opportunities and
Challenges of Commercializing Stem Cell Research.”
The Wisconsin Academy, along with University of Wisconsin-Madison and
the Wisconsin Alumni Research Foundation (WARF), will be hosting the
two-day event titled “A Decade Celebrating
Stem Cells: Changing the Face of Medicine Ten Years Later”
to commemorate the 10th anniversary of the
publication of the first derivation of human embryonic stem cells and to
examine future trends. Other speakers for the event will include
Wisconsin Governor Jim Doyle, Dr. James Thomson, former Governor of
Wisconsin and U.S. Secretary of Health and Human Services Tommy
Thompson, and WARF managing director Carl Gulbrandsen. Dr. West’s
presentation will include a description of historical trends in the
industry of commercializing stem cell technology, and a discussion of
future opportunities for the field. Dr. West will discuss BioTime’s
stem cell research that is focused on opportunities for near-term
revenues in the development and marketing of products derived from stem
cells, and Dr. West will also announce new developments in BioTime’s
stem cell program.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, develops blood plasma
volume expanders, blood replacement solutions for hypothermic (low
temperature) surgery, organ preservation solutions, and technology for
use in surgery, emergency trauma treatment and other applications.
BioTime's lead product Hextend is manufactured and distributed in the
U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under
exclusive licensing agreements.
BioTime has recently entered the field of regenerative medicine through
its wholly owned subsidiary Embryome
Sciences, Inc. where it plans to develop new medical and research
products using embryonic stem cell technology. Additional information
about BioTime can be found on the web at www.biotimeinc.com.
Hextend®, PentaLyte®,
HetaCool®, EmbryomicsTM,
ESpyTM, and ESpanTM,
are trademarks of BioTime, Inc.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,”
“believes,” “plans,”
“anticipates,” “expects,”
“estimates,”)
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0
